Tue, Mar 4, 10:00 AM, Zacks Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.
Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products. Its lead program, sebelipase alfa, is a recombinant human lysosomal acid lipase (LAL) under clinical investigation for the treatment of patients with early onset and late onset LAL Deficiency. In addition to sebelipase alfa, Co. is investigating protein therapeutic programs for other diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and additional programs for other life-threatening conditions.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.